Omaveloxolone + Placebo
Phase 3Recruiting 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Jun 9, 2025 โ Nov 22, 2029
NCT ID
NCT06953583About Omaveloxolone + Placebo
Omaveloxolone + Placebo is a phase 3 stage product being developed by Biogen for Friedreich Ataxia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06953583. Target conditions include Friedreich Ataxia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06953583 | Phase 3 | Recruiting |
Competing Products
20 competing products in Friedreich Ataxia